Lymphoma Clinical Trials at the Mario Lemieux Center for Blood Cancers

To learn more or speak with a trial coordinator, please call 412-864-6600.

This Phase 2 trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment or that has returned after a period of improvement. Onalespib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Principal Investigator: Kathleen Dorritie, MD
Sponsor: National Cancer Institute

View eligibility criteria and the full trial at ClinicalTrials.gov.

The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma. Participants will be randomized to receive either pembrolizumab or brentuximab vedotin (BV) for up to 35 three-week cycles of treatment.

The primary hypotheses of this study are that treatment with pembrolizumab prolongs Progression-free Survival (PFS) and Overall Survival (OS) in participants with relapsed or refractory Classical Hodgkin Lymphoma compared to treatment with BV.

Principal Investigator: Jing Hou, MD, PhD
Sponsor: Merck Sharp & Dohme Corp.

View eligibility criteria and the full trial at ClinicalTrials.gov.

This randomized Phase 3 trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.

Principal Investigator: Kathleen Dorritie, MD
Sponsor: National Cancer Institute

View eligibility criteria and the full trial at ClinicalTrials.gov.